DX 506
Alternative Names: DX-506Latest Information Update: 28 Jul 2024
At a glance
- Originator DermaXon
- Class Anti-inflammatories; Antivirals; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; COVID 2019 infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Jul 2024 No recent reports of development identified for research development in COVID-2019-infections in USA
- 09 Jun 2020 Early research in Autoimmune disorders in USA (unspecified route), prior to June 2020 (DermaXon pipeline, June 2020)